Exhibitors Search
Biobytes Inc.
Booth no.
H50
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|1 Kangwondaehak-gil, Chuncheon-si, Gangwon-do, Republic of Korea |
|
Tel
|
|+82--- |
|
Exhibits
|
| Biobank Cohort Data-Driven Drug Discovery for Sarcopenia |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup , Digital Health / Medical Device Company |
Exhibitor Information
Biobytes is a sarcopenia-focused drug discovery company established in December 2023. Led by an orthopedic surgeon and sarcopenia research expert, the company consists of professionals in AI, biotechnology, and commercialization. Biobytes has established M-Bank, the world’s first multicenter sarcopenia patient biobank, and has secured blood samples, muscle tissue, physical performance, clinical, and genomic data from approximately 800 patients and controls as of August 2026. Based on M-Bank, the company is developing Sarco-Finding, an AI- and genomics-driven platform for biomarker and therapeutic target discovery. It also operates MyoTest, an AI-based diagnostic support solution for sarcopenia, and health functional food products for muscle and sleep management. Biobytes achieved sales of KRW 115 million in 2024, KRW 691 million in 2025, and KRW 700 million in the first half of 2026.
Exhibit Description
1. Sarco-Finding Platform
An AI-powered biomarker discovery platform for sarcopenia, cancer, metabolic and chronic diseases, integrating GWAS/GRS, druggability, network analysis and biological validation.
2. Sarcopenia Biobank (M-Bank)
The world’s first multicenter sarcopenia patient biobank, integrating blood, muscle tissue, physical performance, clinical and genomic data. As of Aug. 2026, data from approx. 800 patients and controls have been collected, with a target of 3,000 by 2027, supporting MyoTest, drug discovery and data-driven research.
3. MyoTest
An AI-based diagnostic support software for predicting sarcopenia risk.
4. Health Functional Foods
Biact Tab., Nyrex Tab. and EasyRest are products designed to support muscle and sleep health.
An AI-powered biomarker discovery platform for sarcopenia, cancer, metabolic and chronic diseases, integrating GWAS/GRS, druggability, network analysis and biological validation.
2. Sarcopenia Biobank (M-Bank)
The world’s first multicenter sarcopenia patient biobank, integrating blood, muscle tissue, physical performance, clinical and genomic data. As of Aug. 2026, data from approx. 800 patients and controls have been collected, with a target of 3,000 by 2027, supporting MyoTest, drug discovery and data-driven research.
3. MyoTest
An AI-based diagnostic support software for predicting sarcopenia risk.
4. Health Functional Foods
Biact Tab., Nyrex Tab. and EasyRest are products designed to support muscle and sleep health.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : Sarco-Finding Platform- Discover diagnostic and therapeutic biomarkers through GWAS/GRS → Druggability → AI Network → biological pathway validation. - Generate milestone revenue via early preclinical licensing, while advancing high-potential biomarkers through in-house pipelines. - Enhance biomarker validity by expanding the sarcopenia biobank cohort. - Validated biomarkers are expected to have a market value of KRW 20?600 billion. - Identify muscle mass and quality targets through integrated genomic/transcriptomic analysis and experimental validation. - Build pipelines around 3 strategies: ① energy metabolism recovery, ② overcoming anabolic resistance, and ③ NMJ restoration for neuromuscular function. - Tier biomarkers by druggability and biological pathways to select optimal drug targets.
-
Product Name : Sarcopenia Biobank (M-Bank)- Established the world’s first multicenter sarcopenia patient biobank, managing blood samples, muscle tissue, physical performance, and diverse clinical and genomic data. - As of August 2026, data from approximately 800 patients and controls have been secured, with targets of 2,000 participants by the end of 2026 and 3,000 by 2027. The data are utilized not only to enhance the performance of MyoTest, but also for drug development and data-driven research.
-
Product Name : MyoTest- 'MyoTest' is an AI-powered solution that predicts the risk of sarcopenia in approximately one minute using health screening data, grip strength, and questionnaire responses. - Currently used as a wellness solution in over 30 hospitals and clinics, MyoTest is also provided via API to major companies including Hyundai E&C, Kyobo Life Insurance, and NH Life Insurance. A confirmatory clinical trial for Class II medical device approval is currently underway, with regulatory approval being pursued.
KYUNGYON EXHIBITION CORP.
